Keywords: Sanofi-Aventis, Teriflunomide, Multople sclerosis, Relapse, Brainn disease activity

Sanofi-Aventis’ oral drug teriflunomide reduces relapses in multiple sclerosis patients by 31%

Article | 18 October 2010

Print This

French drug major Sanofi-Aventis (Euronext: SAN) announced positive results from the two year Phase III TEMSO study of teriflunomide, a ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in